Key clinical point: Frontline rituximab can lower the risk of late relapse in patients with diffuse large B-cell lymphoma (DLBCL).
Major finding: Patients who received frontline treatment with rituximab had a lower risk of late relapse (P less than .001), compared with patients who did not receive rituximab upfront.
Study details: Retrospective study of 1,113 DLBCL patients.
Disclosures: The authors reported relationships with Celgene, Roche, Janssen, MEI Pharma, Astra Zeneca, Celltrion Healthcare, AbbVie, Gilead, Takeda, Sunesis, Morphosys, and Sanofi.
Vannata B et al. Br J Haematol. 2019 Aug 5. doi: 10.1111/bjh.16106.